Ayr Wellness Acquires Tahoe Hydroponics

AYR Wellness Inc. (OTCQX: AYRWF) (CSE:AYR.A) has closed the acquisition of Tahoe Hydroponics Company, LLC.

AYR Wellness Inc. (OTCQX:AYR) has closed the acquisition of Tahoe Hydroponics Company, LLC.

On July 19, 2021, Ayr announced a definitive purchase agreement to acquire Tahoe Hydro, and on February 7, 2022, Ayr and Tahoe Hydro entered into an interim management services agreement. With this closing, Ayr has assumed 100% of the membership interests of Tahoe Hydro. At close the company paid $1.5 million in cash consideration and issued 232,795 exchangeable shares, each exchangeable for one listed share. The closing of NV Green, Inc., which produces concentrates and is the other part of the acquisition, has not yet closed. Upon the expected closing of NV Green, AYR anticipates issuing an additional 58,196 exchangeable shares and no further cash consideration.

“I am thrilled that we have finalized our acquisition of Tahoe Hydro,” stated David Goubert, president & CEO of Ayr. “Although the teams and operations have been integrated since February 2022, we are pleased to make the combination official. Finalizing this transaction underscores our commitment to building depth in our core markets such as Nevada, where we have leading market share along with a differentiated footprint.”

Photo: Benzinga edit with photos by jarmoluk and lindsayfox on Pixabay

 

Related News

New Mexico's Strong March Cannabis Sales While Massachusetts Sees Prices Drop Amid Sector Downturn

Cannabis MSO Exists Arizona, Analyst Calls It 'A Good Move' And Here's Why

Janet Yellen Says Regulators Seeking Solutions For Marijuana Banking, Sen. Bennet Calls Cannabis More Stable Than Crypto

 

Total
0
Shares
Related Posts
Read More

Zoom Had Disappointing Quarter, Faces Transition Year: Here’s Why Some Analysts Are Cutting Price Targets

Video communications company Zoom Video Communications Inc (NASDAQ: ZM) reported earnings per share (EPS) that beat Street estimates and revenue which missed Street estimates on Monday. Analysts sized up the latest quarterly report and the company’s guidance.

ZM

Read More

Vanda Pharmaceuticals Announces Publication Of An Article On “The Efficacy Of Tradipitant In Patients With Diabetic And Idiopathic Gastroparesis In Phase III Randomized Placebo-Controlled Clinical Trial” In The Clinical Gastroenterology And Hepatology

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the publication of an article titled "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized

VNDA